Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial (075)

Xiaohua Wu, Jiafu Ji, Hanmei Lou, Yunxia Li, Mei Feng, Nong Xu, Yuzhi Li, Jing Wang, Yi Huang, Ge Lou, Ruifang An, Changzheng Li, Qi Zhou, Xin Huang, Enfeng Zhao, Tianshu Liu, Qingxia Fan, Guiling Li, Baiyong Li, Yu Xia